Evidence map›Paper›PMID 37752742›Full record

Observational studyESC heart failure2023

Effects of door-to-tolvaptan time on short-term clinical outcome in patients with acute heart failure.

Ryohei Nomura, Tetsuji Morishita, Yusuke Sato, Daisetu Aoyama, Tomohiro Shimizu, Hiroyasu Uzui, Akira Nakano, Hiroshi Tada

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Door-to-Diuretic Time and Outcomes in Acute Heart Failure: A Scoping Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Article
  3. Importance of early use of tolvaptan in hyponatremic acutely decompensated heart failure patients, a retrospective study.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025
    Article
  4. Observational
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ryohei NomuraDivision of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Tetsuji MorishitaDepartment of Internal Medicine, Matsunami General Hospital, Gifu, Japan.
Yusuke SatoDivision of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.ORCID 0000-0003-2897-4766
Daisetu AoyamaDivision of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Tomohiro ShimizuDivision of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Hiroyasu UzuiDivision of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Akira NakanoDepartment of Cardiology, Hikone Municipal Hospital, Hikone, Japan.
Hiroshi TadaDivision of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
University of Fukui · JPHikone Central Hospital · JPMatsunami General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWe investigated the effects of door-to-tolvaptan (D2T) time on short-term urine volume and in-hospital clinical outcomes in patients with acute heart failure (AHF). METHODS AND

resultsPatients with AHF, treated with tolvaptan at two hospitals, were enrolled in this retrospective observational study. The D2T time was defined as the time elapsed from the arrival of a patient at a participating hospital to the first administration of tolvaptan. The group with the D2T time within 6 h was defined as the 'early group'. The primary outcome was 48-h urine volume. The secondary outcomes were in-hospital death, length of hospital stay, and worsening renal function (WRF) incidence. A restricted cubic spline model was used to evaluate the presence of a nonlinear association between the D2T time and 48-h urine volume and the odds ratio of WRF incidence. Our study included a total of 138 patients with AHF who were started on tolvaptan after hospitalization. The median D2T time was 5.3 h (interquartile range: 3.0-31.9 h). Seventy-four patients (53.6%) were classified to be in the early group. Baseline characteristics were similar in the two groups: mean age (85.4 ± 9.6 years vs. 84.5 ± 9.5 years; P = 0.59) and male sex (n = 22 [33.3%] vs. n = 29 [46%]; P = 0.16), except that patients in the early group had higher systolic blood pressure than those in the delayed group (138.2 ± 22.9 vs. 125.7 ± 21.7; P = 0.001). The initial tolvaptan dose in the delayed group was much lower than that in the early group (7.5 [7.5, 7.5] vs. 7.5 [5.6, 7.5] mg; P = 0.01). Total urine volume in 48 h did not differ in the early and delayed groups (4113 ± 1758 mL vs. 4201 ± 1893 mL; P = 0.80). The relationship between D2T time and total urine volume within 48 h increased slightly, with a peak at a D2T time of 15 h, and gradually decreased, thereafter. In-hospital death and the length of hospital stay did not differ significantly between the two groups (n = 1, 1.3% vs. n = 4, 6.3%; P = 0.18, and 5.0 [12.0, 30.0] vs. 22.0 [14.5, 30.0] days; P = 0.17, respectively). Notably, the restricted cubic spline model for the odds ratio of WRF incidence increased as the D2T time was delayed (P for effect<0.01).

conclusionsThe shorter D2T time did not affect the short-term urine volume and in-hospital outcomes but reduced the risk of WRF incidence in patients with AHF.

Indexed as

Antidiuretic Hormone Receptor AntagonistsHeart FailureAgedAged, 80 and overBenzazepinesHospital MortalityHumansMaleRetrospective StudiesTolvaptanAntidiuretic Hormone Receptor AntagonistsBenzazepinesTolvaptanAcute heart failureDoor-to-diuretic timeTolvaptanWorsening renal function

Identifiers

PMID37752742
PMCPMC10682855
OpenAlexW4387077123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.